Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 30/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

57%

4 trials in Phase 3/4

Results Transparency

67%

4 of 6 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 3

4(57.1%)

Phase 1

2(28.6%)

Phase 2

1(14.3%)

7Total

Phase 3(4)

Phase 1(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06431256Phase 3Terminated

Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years With ADHD

Role: lead

NCT01907360Phase 1Completed

Pharmacokinetics of HLD200 in Children and Adolescents With ADHD

Role: lead

NCT02520388Phase 3Completed

A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting

Role: lead

NCT02493777Phase 3Completed

A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting

Role: lead

NCT02884544Phase 2Completed

A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD

Role: lead

NCT02255513Phase 3Completed

A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD

Role: lead

NCT01886469Phase 1Completed

A Phase II, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of Modified Release Amphetamine (HLD100, Formulations B, C and E)) in Adolescents and Children With Attention-Deficit Hyperactivity Disorder (ADHD)

Role: lead

All 7 trials loaded